Seroatlas · Human Serome Atlas

SLC29A1

Equilibrative nucleoside transporter 1

Also known as: ENT1, S29A1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q99808
Gene
SLC29A1
Ensembl
ENSG00000112759
Chromosome
6
Canonical length
456 aa
Protein class
Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters

OverviewNCBI Gene

This gene is a member of the equilibrative nucleoside transporter family. The gene encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

456 residues, UniProt reviewed canonical sequence.

>Q99808|SLC29A1
     1  MTTSHQPQDR YKAVWLIFFM LGLGTLLPWN FFMTATQYFT NRLDMSQNVS LVTAELSKDA
    61  QASAAPAAPL PERNSLSAIF NNVMTLCAML PLLLFTYLNS FLHQRIPQSV RILGSLVAIL
   121  LVFLITAILV KVQLDALPFF VITMIKIVLI NSFGAILQGS LFGLAGLLPA SYTAPIMSGQ
   181  GLAGFFASVA MICAIASGSE LSESAFGYFI TACAVIILTI ICYLGLPRLE FYRYYQQLKL
   241  EGPGEQETKL DLISKGEEPR AGKEESGVSV SNSQPTNESH SIKAILKNIS VLAFSVCFIF
   301  TITIGMFPAV TVEVKSSIAG SSTWERYFIP VSCFLTFNIF DWLGRSLTAV FMWPGKDSRW
   361  LPSLVLARLV FVPLLLLCNI KPRRYLTVVF EHDAWFIFFM AAFAFSNGYL ASLCMCFGPK
   421  KVKPAEAETA GAIMAFFLCL GLALGAVFSF LFRAIV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC29A1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
11
Mean surface accessibility (rSASA)
0.28
Highest tissue expression
135 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 135 nTPM
  • heart muscle: 130 nTPM
  • blood vessel: 119 nTPM
  • colon: 112 nTPM
  • adipose tissue: 111 nTPM
  • adrenal gland: 108 nTPM

Single-cell type

  • extravillous trophoblasts: 279 nCPM
  • cytotrophoblasts: 267 nCPM
  • oocytes: 253 nCPM
  • migrating cytotrophoblasts: 215 nCPM
  • adrenal medulla cells: 128 nCPM
  • granulosa cells: 118 nCPM

Immune cell

  • eosinophil: 1,049 nTPM
  • plasmacytoid DC: 40 nTPM
  • intermediate monocyte: 39 nTPM
  • non-classical monocyte: 33 nTPM
  • basophil: 22 nTPM
  • classical monocyte: 12 nTPM

Brain region

  • pons: 38 nTPM
  • cerebral cortex: 36 nTPM
  • cerebellum: 33 nTPM
  • hypothalamus: 32 nTPM
  • medulla oblongata: 30 nTPM
  • white matter: 29 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC29A1.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 70 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Hemolytic disease of fetus OR newborn due to isoimmunization

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.38
gnomAD pLI
0.9
gnomAD missense Z
0.72
DepMap mean gene effect
-0.02
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SLC29A1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC29A1 as an antibody target. Whether an autoantibody or antibody against SLC29A1 could matter depends on whether native SLC29A1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC29A1 is annotated at the cell surface, where native SLC29A1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC29A1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC29A1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...